Literature DB >> 19965675

Granzyme B is not required for regulatory T cell-mediated suppression of graft-versus-host disease.

Sheng F Cai1, Xuefang Cao, Anjum Hassan, Todd A Fehniger, Timothy J Ley.   

Abstract

Regulatory T (T(reg)) cells can suppress a wide variety of immune responses, including antitumor and alloimmune responses. The mechanisms by which T(reg) cells mediate their suppressive effects depend on the context of their activation. We previously reported that granzyme B is important for T(reg) cell-mediated suppression of antitumor immune responses. We therefore hypothesized that granzyme B may likewise be important for suppression of graft-versus-host disease (GVHD). We found that allogeneic mismatch induces the expression of granzyme B in mixed lymphocyte reactions and in a model of graft-versus-host disease (GVHD). However, wild-type and granzyme B-deficient T(reg) cells were equally able to suppress effector T (T(eff)) cell proliferation driven by multiple stimuli, including allogeneicantigen-presenting cells. Surprisingly, adoptive transfer of granzyme B-deficient T(reg) cells prevented GVHD lethality, suppressed serum cytokine production in vivo, and prevented target organ damage. These data contrast strikingly with our previous study, which demonstrated that granzyme B plays a nonredundant role in T(reg) cell-mediated suppression of antitumor responses. Taken together, these findings suggest that targeting specific T(reg) cell-suppressive mechanisms, such as granzyme B, may be therapeutically beneficial for segregating GVHD and graft-versus-tumor immune responses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19965675      PMCID: PMC2832813          DOI: 10.1182/blood-2009-07-233676

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  42 in total

Review 1.  Modulation of graft-versus-host disease: role of regulatory T lymphocytes.

Authors:  Allan D Hess
Journal:  Biol Blood Marrow Transplant       Date:  2006-01       Impact factor: 5.742

Review 2.  A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3.

Authors:  Jason D Fontenot; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2005-04       Impact factor: 25.606

Review 3.  Hematopoietic stem-cell transplantation.

Authors:  Edward A Copelan
Journal:  N Engl J Med       Date:  2006-04-27       Impact factor: 91.245

4.  Activated CD4+CD25+ T cells selectively kill B lymphocytes.

Authors:  Dong-Mei Zhao; Angela M Thornton; Richard J DiPaolo; Ethan M Shevach
Journal:  Blood       Date:  2006-01-17       Impact factor: 22.113

5.  Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice.

Authors:  Jeong M Kim; Jeffrey P Rasmussen; Alexander Y Rudensky
Journal:  Nat Immunol       Date:  2006-11-30       Impact factor: 25.606

6.  The role of Foxp3+ T cells in long-term efficacy of prophylactic and therapeutic mucosal tolerance induction in mice.

Authors:  B Winkler; K Hufnagl; A Spittler; M Ploder; E Kállay; S Vrtala; R Valenta; M Kundi; H Renz; U Wiedermann
Journal:  Allergy       Date:  2006-02       Impact factor: 13.146

7.  Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism.

Authors:  David C Gondek; Li-Fan Lu; Sergio A Quezada; Shimon Sakaguchi; Randolph J Noelle
Journal:  J Immunol       Date:  2005-02-15       Impact factor: 5.422

8.  Suppression of allergic airway inflammation by helminth-induced regulatory T cells.

Authors:  Mark S Wilson; Matthew D Taylor; Adam Balic; Constance A M Finney; Jonathan R Lamb; Rick M Maizels
Journal:  J Exp Med       Date:  2005-11-07       Impact factor: 14.307

9.  Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease.

Authors:  Katharina Lahl; Christoph Loddenkemper; Cathy Drouin; Jennifer Freyer; Jon Arnason; Gérard Eberl; Alf Hamann; Hermann Wagner; Jochen Huehn; Tim Sparwasser
Journal:  J Exp Med       Date:  2007-01-02       Impact factor: 14.307

10.  Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells.

Authors:  Kuibeom Ko; Sayuri Yamazaki; Kyoko Nakamura; Tomohisa Nishioka; Keiji Hirota; Tomoyuki Yamaguchi; Jun Shimizu; Takashi Nomura; Tsutomu Chiba; Shimon Sakaguchi
Journal:  J Exp Med       Date:  2005-09-26       Impact factor: 14.307

View more
  13 in total

Review 1.  Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?

Authors:  Celalettin Ustun; Jeffrey S Miller; David H Munn; Daniel J Weisdorf; Bruce R Blazar
Journal:  Blood       Date:  2011-08-31       Impact factor: 22.113

Review 2.  Phosphoinositide 3-kinase δ is a regulatory T-cell target in cancer immunotherapy.

Authors:  Ee Lyn Lim; Klaus Okkenhaug
Journal:  Immunology       Date:  2019-07       Impact factor: 7.397

3.  Granzyme B-Mediated Activation-Induced Death of CD4+ T Cells Inhibits Murine Acute Graft-versus-Host Disease.

Authors:  Wei Du; Nicholas D Leigh; Guanglin Bian; Rachel E O'Neill; Lin Mei; Jingxin Qiu; George L Chen; Theresa Hahn; Hong Liu; Philip L McCarthy; Xuefang Cao
Journal:  J Immunol       Date:  2015-09-21       Impact factor: 5.422

4.  In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia.

Authors:  Jaebok Choi; Julie Ritchey; Julie L Prior; Matthew Holt; William D Shannon; Elena Deych; David R Piwnica-Worms; John F DiPersio
Journal:  Blood       Date:  2010-04-27       Impact factor: 22.113

5.  Blockade of Host β2-Adrenergic Receptor Enhances Graft-versus-Tumor Effect through Modulating APCs.

Authors:  Hemn Mohammadpour; Rachel O'Neil; Jingxin Qiu; Philip L McCarthy; Elizabeth A Repasky; Xuefang Cao
Journal:  J Immunol       Date:  2018-02-14       Impact factor: 5.422

6.  Regulatory T-Cell Therapy for Graft-versus-host Disease.

Authors:  Jessica Heinrichs; David Bastian; Anandharaman Veerapathran; Claudio Anasetti; Brain Betts; Xue-Zhong Yu
Journal:  J Immunol Res Ther       Date:  2016-04-28

7.  CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cells.

Authors:  Jiehua Zhou; Asad Bashey; Ruikun Zhong; Sue Corringham; Karen Messer; Minya Pu; Wenxue Ma; Theresa Chut; Robert Soiffer; Rachel C Mitrovich; Israel Lowy; Edward D Ball
Journal:  Biol Blood Marrow Transplant       Date:  2010-08-14       Impact factor: 5.742

8.  Serine protease inhibitor 6 plays a critical role in protecting murine granzyme B-producing regulatory T cells.

Authors:  Jamil Azzi; Nikolaos Skartsis; Marwan Mounayar; Ciara N Magee; Ibrahim Batal; Christopher Ting; Robert Moore; Leonardo V Riella; Shunsuke Ohori; Rozita Abdoli; Brian Smith; Paolo Fiorina; Dean Heathcote; Tannous Bakhos; Philip G Ashton-Rickardt; Reza Abdi
Journal:  J Immunol       Date:  2013-08-02       Impact factor: 5.422

9.  Granzyme A Is Required for Regulatory T-Cell Mediated Prevention of Gastrointestinal Graft-versus-Host Disease.

Authors:  Sarvari Velaga; Sya N Ukena; Ulrike Dringenberg; Christina Alter; Julian Pardo; Olivia Kershaw; Anke Franzke
Journal:  PLoS One       Date:  2015-04-30       Impact factor: 3.240

10.  Granzyme B Contributes to the Optimal Graft-Versus-Tumor Effect Mediated by Conventional CD4+ T Cells.

Authors:  Wei Du; Nicholas D Leigh; Guanglin Bian; Emad Alqassim; Rachel E O'Neill; Lin Mei; Jingxin Qiu; Hong Liu; Philip L McCarthy; Xuefang Cao
Journal:  J Immunol Res Ther       Date:  2016-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.